Real-World trial tests three drug combinations for rare lymphoma
NCT ID NCT07492407
Summary
This study aims to compare how well three different treatment combinations work for people newly diagnosed with marginal zone B-cell lymphoma, a type of blood cancer. Researchers will follow 131 patients receiving either BR, R2, or OR2 treatment regimens to see which approach best controls the disease with the fewest side effects. The study focuses on real-world treatment outcomes rather than tightly controlled laboratory conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MZL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.